Cerus (CERS) Corporation announced it has been awarded an additional $7.2M contract amendment by the U.S. Department of Defense Industrial Base Analysis and Sustainment program for the development of lyophilized INTERCEPT Fibrinogen Complex, or IFC, to treat bleeding due to trauma. The additional funding will support CRYO-FIRST, a randomized study comparing the use of pre-thawed IFC to conventional cryoprecipitated antihemophilic factor in trauma-associated hemorrhagic shock patients. This is additive to the approximately $18M currently provided under Cerus’ contract with the DoD.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERS: